📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Neurogene

1.1 - Company Overview

Neurogene Logo

Neurogene

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of genetic medicines for neurological disorders, offering EXACT gene therapy technology for controlled and balanced gene expression, a platform that delivers consistent transgene expression (utilized in Rett syndrome) with CNS and ocular delivery, robust CGMP-compliant internal manufacturing for research and clinical material, and clinical trials to evaluate safety and efficacy in genetic diseases.

Products and services

  • Gene Therapy Platform Technology: Consistency-optimized platform delivers consistent transgene expression, utilized in Rett syndrome treatment and adaptable to other indications, supporting consistent therapeutic expression across applications
  • EXACT gene therapy technology: Controlled-expression system engineered for treating complex genetic diseases by precisely regulating gene expression, with applicability across various genetic disorders requiring balanced transgene activity
  • Robust Internal Manufacturing Capabilities: CGMP-compliant operations produce research and clinical grade material using scalable platform processes, supporting internal production of gene therapy materials

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Neurogene

Atsena Therapeutics Logo

Atsena Therapeutics

HQ: United States Website
  • Description: Provider of clinical-stage gene therapies and AAV delivery technologies for inherited retinal diseases: ATSN-101 for GUCY2D-associated LCA1, ATSN-201 leveraging AAV.SPR for XLRS, and ATSN-301 dual AAV vectors for MYO7A-associated USH1B; plus laterally spreading capsids for broad retinal delivery, dual-vector methods for large genes, and intravitreal capsids that evade neutralizing antibodies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Atsena Therapeutics company profile →
Kriya Therapeutics Logo

Kriya Therapeutics

HQ: United States Website
  • Description: Provider of gene therapies for ophthalmology, neurology, and metabolic diseases, including KRIYA-825 for geographic atrophy (inhibiting C3/C5; one-time suprachoroidal), KRIYA-586 for thyroid eye disease (blocking IGF1 receptor), KRIYA-839 for diabetes (insulin and glucokinase), KRIYA-497 for NASH (FGF21), and KRIYA-748 and KRIYA-382 for trigeminal neuralgia and focal epilepsy via chemogenetically gated ion channels.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Kriya Therapeutics company profile →
SalioGen Logo

SalioGen

HQ: United States Website
  • Description: Provider of non-viral Gene Coding technology enabling precise integration of large or multiple whole genes without double-strand breaks or guide RNA, and of programs including SGT-1001 for Stargardt disease, one-time genetic medicines for cystic fibrosis, CAR-T cell engineering for cancer and autoimmune diseases with tissue-specific integration, and therapies for inherited retinal diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full SalioGen company profile →
EG 427 Logo

EG 427

HQ: France Website
  • Description: Provider of pinpoint gene therapy using non-replicative HSV-1 vectors. Offers EG110A for neurogenic bladder dysfunction and overactive bladder; a platform delivering large genes with precise control and long-term expression for peripheral nervous system disorders; vector engineering with specific promoters for targeted sensory or autonomic neuronal subsets; and R&D expanding to chronic indications, including central nervous system neurons.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full EG 427 company profile →
Genenta Logo

Genenta

HQ: Italy Website
  • Description: Provider of gene transfer therapy for cancer, including Temferon, a lentiviral hematopoietic stem progenitor cell immunotherapy enabling controlled, targeted interferon-α expression within tumors to generate immune responses to TEMs-positive cancers. Offers a proprietary cell-based platform using hematopoietic stem cells to deliver therapeutic payloads in the tumor microenvironment for durable, safe treatment of solid tumors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Genenta company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Neurogene

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Neurogene

2.2 - Growth funds investing in similar companies to Neurogene

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Neurogene

4.2 - Public trading comparable groups for Neurogene

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Neurogene

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Neurogene

What does Neurogene do?

Neurogene is a provider of genetic medicines for neurological disorders, offering EXACT gene therapy technology for controlled and balanced gene expression, a platform that delivers consistent transgene expression (utilized in Rett syndrome) with CNS and ocular delivery, robust CGMP-compliant internal manufacturing for research and clinical material, and clinical trials to evaluate safety and efficacy in genetic diseases.

Who are Neurogene's competitors?

Neurogene's competitors and similar companies include Atsena Therapeutics, Kriya Therapeutics, SalioGen, EG 427, and Genenta.

Where is Neurogene headquartered?

Neurogene is headquartered in United States.

How many employees does Neurogene have?

Neurogene has 1,000 employees 🔒.

When was Neurogene founded?

Neurogene was founded in 2010 🔒.

What sector and industry vertical is Neurogene in?

Neurogene is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Neurogene

Who are the top strategic acquirers in Neurogene's sector and industry

Top strategic M&A buyers and acquirers in Neurogene's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Neurogene?

Top strategic M&A buyers groups and sectors for Neurogene include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Neurogene's sector and industry vertical

Which are the top PE firms investing in Neurogene's sector and industry vertical?

Top PE firms investing in Neurogene's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Neurogene's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Neurogene's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Neurogene's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Neurogene include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Neurogene's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Neurogene?

The key public trading comparables and valuation benchmarks for Neurogene include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Neurogene for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Neurogene with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Neurogene's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Neurogene with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Neurogene's' sector and industry vertical?

Access recent funding rounds and capital raises in Neurogene's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Neurogene